相关实验视频

Updated: Jan 12, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

对PLA2R表位扩散进行临床研究,以预测一次性膜性脏病中蛋白尿症缓解的预测

Xueyang Cheng¹, Meiyi Zhou¹, Caimei Chen¹

¹Department of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.

Frontiers in immunology

|November 7, 2025

概括

M型脂酶A2受体 (PLA2R) 的皮层扩散是初级膜性病 (PMN) 治疗结果的重要预测因素. 这一发现突显了其作为PMN患者预后生物标志物的潜力.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
生物标志物发现发现

背景情况:

M型脂酶A2受体 (PLA2R) 是原发性膜性病 (PMN) 中的主要自身抗原,占病例的70-80%.
循环中的抗PLA2RIgG抗体是监测PMN活性和治疗反应的已确立生物标志物.
新出现的证据表明,针对特定PLA2R域和表皮质传播的抗体可能与疾病严重程度和治疗耐药性相关,尽管临床相关性仍有争议.

研究的目的:

研究与PMN患者的总抗PLA2RIgG水平相比,PLA2R表位扩散的预后价值.
评估表位扩散作为PMN治疗结果的预测生物标志物的临床实用性.

主要方法:

74名 PMN 患者的回顾性研究活检证明 PMN 患者的活检证明 PMN 患者至少6个月的随访.
在基线,6个月和12个月收集的血清样本.
测量PLA2R-IgG,域特异性抗体 (CysR-, CTLD1-, CTLD7/8-IgG/IgG4),以及使用时间解析光免疫测试的抗素抗体 (ARA).
后勤回归和ROC曲线分析以确定预后因素;患者按循环胺 (CTX) 和修仙药 (RTX) 治疗分组.

主要成果:

与环胺 (CTX) 相比,Rituximab (RTX) 治疗导致12个月的抗体清除速度更快,免疫缓解率更高.
在RTX组中,表皮质扩散显著减少了6个月,并且在非复发的患者中检测到抗素抗体 (ARAs).
在RTX组中,皮层扩散被确定为6个月后非缓解的独立风险因素 (AUC = 0.932).

结论:

与CTX相比,Rituximab (RTX) 在12个月内显示出更高的免疫性缓解率.
在PMN患者中,RTX治疗6个月后,PLA2R表位扩散是临床缓解的重要独立风险因素.
在非缓解的病例中,ARAs的存在可能表明替代疗法 (如奥比努祖马布) 对非缓解病例的潜在益处.

关键词:

这就是 PLA2R.抗利图西马布抗体的抗体标本正在扩散,正在扩散.原发性膜性脏病 - 一次性膜性脏病.这就是Rituximab.

更多相关视频

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

相关概念视频

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...